Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines

Defective DNA mismatch repair (dMMR) is associated with many cancer types including colon, gastric, endometrial, ovarian, hepatobiliary tract, urinary tract, brain and skin cancers. Lynch syndrome – a hereditary cause of dMMR – confers increased lifetime risk of malignancy in different organs and tissues. These Lynch syndrome pathogenic alleles are widely present in humans at a 1:320 population frequency of a single allele and associated with an up to 80% risk of developing microsatellite unstable cancer (microsatellite instability – high, or MSI-H). Advanced MSI-H tumors can be effectively treated with checkpoint inhibitors (CPI), however, that has led to response rates of only 30-60% despite their high tumor mutational burden and favorable immune gene signatures in the tumor microenvironment (TME). We and others have characterized a subset of MSI-H associated highly recurrent frameshift mutations that yield shared immunogenic neoantigens. These frameshifts might serve as targets for off-the-shelf cancer vaccine designs. In this review we discuss the current state of research around MSI-H cancer vaccine development, its application to MSI-H and Lynch syndrome cancer patients and the utility of MSI-H as a biomarker for CPI therapy. We also summarize the tumor intrinsic mechanisms underlying the high occurrence rates of certain frameshifts in MSI-H. Finally, we provide an overview of pivotal clinical trials investigating MSI-H as a biomarker for CPI therapy a...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
According to the American Cancer Society, about 1 in 5 cancers in the US and about 1 in 6 cancer deaths can be linked to poor nutrition, being overweight, not exercising, or alcohol.WebMD Health News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
OHSU's vaccination results are in line with other major Portland health systems.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
The FDA has followed the advice of its advisory panels, approving additional doses of Moderna and J&J vaccines, and opening up people's options by letting them switch vaccine type for their booster.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Infectious Diseases News Alert Source Type: news
Both Iterion and Moleculin are moving their drug candidates through the regulatory pipeline.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
The U.S. Food and Drug Administration has given the O.K. to Covid-19 vaccine "booster" shots made by Cambridge biotech Moderna Inc. Moderna (Nasdaq: MRNA) is now able to make and distribute boosters — third shots identical to each of the first two in the series, but half the amount — for patients 65 and older, adults with underlying medical conditions and adults who are at a high risk for Covid-19 because of their occupati ons or time in institutional settings. The decision comes a few days…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
As the number of Americans getting COVID-19 vaccines has risen, there is a heightened push to provide booster shots to some vaccinated persons to ensure that their immunity continues.Medscape Reader Polls
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news
Even as metro Milwaukee ’s largest private sector employer Advocate Aurora Health said 99% of its employees complied with its Covid-19 vaccine policy, another major area employer, GE Healthcare, said all of its employees must get vaccinated by Dec. 8.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Chem. Commun., 2021, Accepted Manuscript DOI: 10.1039/D1CC03497A, CommunicationAltab Shaikh, Praveen Neeli, Gajalakshmi Singuru, Sravya Panangipalli, Raj Kumar Banerjee, M. Sridhar Reddy, Rajamannar Thennati, B. Surendar Reddy, Srigiridhar Kotamraju Herein, we document a self-assembling octyl-TPP tagged esculetin (Mito-Esc) as a functional, and as a novel small molecule siRNA delivery vector. While Mito-Esc itself induce selective breast cancer cell death,... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
In a recent note, I discused some theories about why the incidence of colonic cancer is increasing in younger patients (see:Why the Increased Incidence of Colonic Cancer Among Younger Americans?). Continuing in this same vein, a recent article I came across raised the issue of multigene panel testing to reveal genetic mutations in the roughly one-third of patents with early onset colonic cancer (see:Multigene Panel Testing Reveals Mutations in One-Third of Early Onset CRC Patients). Below is an excerpt from the article:Although the overall incidence of colorectal cancer (CRC) has been decreasing in the Unite...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Tags: Clinical Lab Industry News Clinical Lab Testing Lab Industry Trends Lab Processes and Procedures Medical Research Preventive Medicine Source Type: blogs
More News: Allergy & Immunology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Colon Cancer | Colorectal Cancer | Endometrial Cancer | Gastric (Stomach) Cancer | Gastroenterology | Gastroschisis Repair | Genetics | HNPCC | Lynch Syndrome | Neurology | Ovarian Cancer | Ovaries | Skin | Vaccines